PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 29871906.
- Also identified by DOI 10.1158/1078-0432.CCR-18-1314.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
PARP inhibitors have transformed treatment for ovarian cancer, a cancer notable for homologous recombination (HR) deficiencies and aberrant DNA repair, especially in the high-grade serous subtype. PARP inhibitors are now approved for recurrent ovarian cancer as maintenance following response to platinum chemotherapy and <i>BRCA</i>-mutated (<i>BRCA</i>m) cancer treatment. <i>Clin Cancer Res; 24(17); 4062-5. ©2018 AACR</i><i>See related article by Ison et al., p. 4066</i>.
Medical subject headings
- Ovarian Neoplasms
- Poly(ADP-ribose) Polymerase Inhibitors